Scholar Rock Holding Corp SRRK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity
-
Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer
-
Scholar Rock to Participate in Upcoming Investor Conferences
-
Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Scholar Rock Reports Second Quarter 2024 Financial Results and Highlights Business Progress
-
Scholar Rock to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
Trading Information
- Previous Close Price
- $8.61
- Day Range
- $8.52–8.80
- 52-Week Range
- $6.23–21.17
- Bid/Ask
- $7.85 / $11.68
- Market Cap
- $692.28 Mil
- Volume/Avg
- 439,577 / 765,307
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 (“TGFβ1”), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 150
- Website
- https://www.scholarrock.com
Comparables
Valuation
|
Metric
|
SRRK
|
SWTX
|
RNA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 5.18 | 4.31 | 3.77 |
Price/Sales | — | 25.82 | 342.53 |
Price/Cash Flow | — | — | — |
Price/Earnings
SRRK
SWTX
RNA
Financial Strength
|
Metric
|
SRRK
|
SWTX
|
RNA
|
|---|---|---|---|
Quick Ratio | 5.81 | 7.49 | 15.61 |
Current Ratio | 6.04 | 7.91 | 15.78 |
Interest Coverage | −30.36 | — | — |
Quick Ratio
SRRK
SWTX
RNA
Profitability
|
Metric
|
SRRK
|
SWTX
|
RNA
|
|---|---|---|---|
Return on Assets (Normalized) | −64.22% | −32.86% | −25.50% |
Return on Equity (Normalized) | −94.44% | −37.78% | −28.88% |
Return on Invested Capital (Normalized) | −67.33% | −42.13% | −33.01% |
Return on Assets
SRRK
SWTX
RNA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Fgnmlwlll | Lwsr | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Xwbdwdbyw | Tbyslrq | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Nfvnksf | Bcmrx | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Gzrnrwp | Tstbpzz | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Scdnszd | Qkqr | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Nyblnyv | Grpjx | $28.0 Bil | |||
| Moderna Inc
MRNA
| Kvhnnfzr | Xkby | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Xppnyyb | Stgg | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Xnrxhwkjz | Nnbtvyw | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Ztnpchqw | Fjxqtq | $12.6 Bil |
United States